Use of Daratumumab for DSA Desensitization for Mismatched Stem Cell Transplantation

Key Points

• Daratumumab effectively reduces donor-specific antibodies, facilitating better outcomes in transplantation.
• A reduction of 70% in donor-specific antibodies was observed after daratumumab treatment.
• Observational analysis of multiple cases highlights the feasibility of using daratumumab for desensitization.
• This approach may enable wider transplant options for patients with mismatched donors.